CU-2010 and CU-2020: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
CSV import |
||
| Line 2: | Line 2: | ||
{{stb}} | {{stb}} | ||
{{short-articles-ni}} | {{short-articles-ni}} | ||
{{No image}} | |||
Latest revision as of 09:10, 10 February 2025
CU-2010 and CU-2020 are synthetic compounds that act as serine protease inhibitors. These were developed in 2010 to replace the use of aprotinin during and after cardiac surgery, including surgeries with cardiopulmonary bypass which cause blood loss and hemorrhagic complications. CU-2010 and CU-2020 were developed to avoid many issues associated with the use of aprotinin, including the risk of an allergic reaction and infection. Since the isolation of aprotinin is expensive, a drug with a simpler synthesis was desired
| This article is a stub. You can help WikiMD by registering to expand it. |
